School of Dentistry, Chung Shan Medical University, Taichung, Taiwan.
J Oral Pathol Med. 2011 Sep;40(8):621-8. doi: 10.1111/j.1600-0714.2011.01015.x. Epub 2011 Feb 22.
Oral squamous cell carcinoma (OSCC) is the sixth most prevalent cancer worldwide. Cancer stem cells (CSC) model theoretically contribute to tumor growth, metastasis, and chemo-radioresistance. Cisplatin is a widely used chemotherapeutic agent for OSCC treatment. The aim of this study was to compare stemness genes expression in chemo-sensitive and chemo-resistant specimens and further explore the potential markers that may lead to induce chemo-resistance in OSCC.
The study method is the treatment of OC2 cells with cisplatin select cisplatin-resistant OC2 cells. Self-renewal ability was evaluated by cultivating parental and cisplatin-resistant OC2 cells within sphere-forming assay after serial passages. Differential expression profile of stemness markers between parental and cisplatin-resistant OC2 cells was elucidated. The parental and cisplatin-resistant OC2 cells were assessed for migration/invasion/clonogenicity tumorigenic properties in vitro. Expression of stemness markers in chemo-sensitive and chemo-resistant patients with OSCC was performed by immunohistochemistry staining in vivo.
Sphere-forming/self-renewal capability was increased in cisplatin-resistant OC2 cells. Cisplatin-resistant OC2 cells highly expressed the stemness markers (Nanog, Oct4, Bmi1, CD117, CD133, and ABCG2). Furthermore, cisplatin-resistant OC2 cells increased migration/invasion/clonogenicity ability. Notably, up-regulation of Oct4 and Nanog expression was significantly observed in cisplatin-resistant patients with OSCC (**P < 0.01).
These data indicate that cancer stem-like properties were expanded during the acquisition of cisplatin resistance in OSCC. Clinically, oral cancer stemness markers (Oct4 and Nanog) overexpression may promote the OSCC's recurrence to resist cisplatin.
口腔鳞状细胞癌(OSCC)是全球第六大常见癌症。癌症干细胞(CSC)模型理论上有助于肿瘤的生长、转移和化疗耐药。顺铂是治疗 OSCC 的常用化疗药物。本研究的目的是比较化疗敏感和耐药标本中的干性基因表达,并进一步探讨可能导致 OSCC 化疗耐药的潜在标志物。
该研究方法是用顺铂处理 OC2 细胞,选择顺铂耐药的 OC2 细胞。通过在传代后进行球体形成实验,评估亲本和顺铂耐药的 OC2 细胞的自我更新能力。阐明亲本和顺铂耐药的 OC2 细胞之间干性标志物的差异表达谱。在体外评估亲本和顺铂耐药的 OC2 细胞的迁移/侵袭/克隆形成肿瘤形成特性。通过免疫组织化学染色在体内评估化疗敏感和耐药的 OSCC 患者中的干性标志物表达。
顺铂耐药的 OC2 细胞的球体形成/自我更新能力增加。顺铂耐药的 OC2 细胞高表达干性标志物(Nanog、Oct4、Bmi1、CD117、CD133 和 ABCG2)。此外,顺铂耐药的 OC2 细胞增加了迁移/侵袭/克隆形成能力。值得注意的是,在顺铂耐药的 OSCC 患者中观察到 Oct4 和 Nanog 表达的上调(**P < 0.01)。
这些数据表明,在 OSCC 获得顺铂耐药的过程中,癌症样干性特性得到了扩展。临床上,口腔癌干性标志物(Oct4 和 Nanog)的过度表达可能会促进 OSCC 的复发以抵抗顺铂。